Loading…
Loading…
Obviously, you raised the guide there. Should we think about that being primarily driven by U.S. or OUS
Wanted to get a sense understanding of your expectations and flexibility, if need be to take actions outside the US
Are you taking actions or advocating either on your own or in conjunction with peers to address persistent unlawful compounding?
we've seen pretty volatile scripts over here the past couple of weeks. And I guess my question is, are the TRx that we're seeing reflective of what you're seeing
your continued confidence on anito-cel approvability based on a single-arm study
there have been a number of cuts across HHS, CDC to start the year across various teams, divisions. Raising uncertainty around potential disruptions
anything you can share there around if you think potential MFN legislation is a priority or possibility in the coming balance of the year?
how does Merck think about the importance and speed it may need to pursue combinations on the back of those data
I wanted to ask you around your confidence in ultimately hitting on OS in the 022 study